<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 27, 1999
MEDQUIST INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
New Jersey 0-19941 22-253 1298
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Number) Identification No.)
Five Greentree Centre, Suite 311, Marlton, New Jersey 08053
(Address of principal executive offices)
(609) 596-8877
(Registrant's telephone number, including area code)
Page 1 of 3
<PAGE>
Item 5. Other Events.
The Company issued a press release on April 28, 1999, a copy of which
is attached hereto as Exhibit 1.1, relating to its previously announced
registered public offering.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits.
1.1 Press Release issued April 28, 1999.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
MEDQUIST INC.
Date: April 29, 1999 By: /s/ John M. Suender
----------------------------------
John M. Suender
Senior Vice President and
General Counsel
Page 2 of 3
<PAGE>
EXHIBIT 1.1
MEDQUIST PUBLIC OFFERING
MARLTON, N.J.-- April 28, 1999 -- MedQuist Inc. (Nasdaq: "MEDQ") announced today
that it has priced a public offering of 4,493,467 shares of common stock at a
price of $33 5/8 per share. Of the 4,493,467 shares being offered, 800,000 are
being sold by MedQuist and 3,693,467 are being sold by existing shareholders.
The underwriters have an option to purchase up to 674,020 additional shares from
MedQuist.
The offering is being co-managed by Goldman, Sachs & Co., BancBoston Robertson
Stephens, Donaldson, Lufkin & Jenrette and Volpe Brown Whelan & Company.
The net proceeds of the 800,000 shares being sold by MedQuist are expected to be
approximately $25.6 million. These proceeds are intended to be used to fund a
substantial portion of MedQuist's pending acquisition of Lanier Transcription
Services, a national provider of medical transcription services.
MedQuist is the leading national provider of medical transcription services, a
key component in the provision of healthcare services. MedQuist serves
approximately 2,300 customers nationwide through its 77 client service centers.
CONTACT: MedQuist Inc., Marlton, NJ
John R. Emery, 609/596-8877
